Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trans fat labeling study

This article was originally published in The Tan Sheet

Executive Summary

FDA is seeking comment on a proposed experimental study of trans fat claims on foods, according to a Federal Register notice slated for publication Feb. 6. The study would "evaluate the effect of various possible disclosure requirements intended to help consumers understand and apply trans fat claims they might see on food products," the agency explains. The proposed study would be conducted online among roughly 2,880 adult respondents, FDA states. Data gathered from the study would be used to "assess likely consumer responses to various disclosure requirements for nutrient content claims." The compliance date for FDA's requirement that products containing trans fat be appropriately labeled was Jan. 1 (1"The Tan Sheet" July 14, 2003, p. 7). Comments on the proposal are due by April 7...

You may also be interested in...



Supplement Trans Fat Label Additions Stipulated Under FDA Final Rule

Manufacturers of dietary supplements that contain more than .5 g of trans fat will be required to list the amount of the ingredient, as well as the amounts of saturated fat and cholesterol, on the Supplement Facts panel by Jan. 1, 2006

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel